Eye health company Bausch + Lomb has received the CE Mark approval in Europe for its LuxLife range of vision intraocular lens (IOL).
This approval comes after the company’s recent introductions of enVista Aspire intermediate-optimised IOLs in the European region and the enVistaEnvy range of vision lenses in the US and Canada.
Go deeper with GlobalData
The preloaded LuxLife IOL is designed to offer individuals continuous vision from distance to near. According to the company, the lens has demonstrated better visual outcomes in a comparative multicentre clinical trial, where it was evaluated against the monofocal LuxGood IOL.
LuxLife IOL is claimed to leverage Pure Refractive Optics (PRO) Technology, featuring a continuous refractive surface across the optical diameter. In addition, this non-diffractive IOL is further enhanced by two Allied Ray Technology (ART) Zones, which effectively control and refocus light rays.
These two technologies of LuxLife make sure no light is lost to the retina.
LuxLife IOL also offers a range of cylinders, extending from +0.75D to +6.00D, allowing surgeons to treat corneal astigmatism of over 0.5D in individuals before undergoing cataract surgery.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe preloaded lens comes with a dual injector system, giving surgeons the flexibility to choose their preferred injection technique while performing implantation.
The company noted that the commercial availability of LuxLife IOLs in Europe is expected in the upcoming weeks, with a toric version of the lens to follow shortly. Bausch + Lomb is also pursuing regulatory approvals in additional countries.
Bausch + Lomb Surgical president Luc Bonnefoy said: “This platform has delivered both quality of vision and patient satisfaction since its introduction.
“LuxLife is an example of how we plan to build on that success by developing premium options designed to meet the evolving needs of surgeons and patients.”
